18-Oct-2018 - oncgnostics GmbH

New financing round at oncgnostics GmbH close

The life sciences company oncgnostics GmbH was able to double its investment of 750,000 euros following the very rapid and successful completion of its second crowd investing campaign on Seedmatch. A group of private investors invests together with beteiligungsmanagement thüringen GmbH (bm|t) in oncgnostics. The company will use the sum for further research and development, conducting studies and intensifying international marketing activities.

For its GynTect cervical cancer test, oncgnostics launched its second crowd investing campaign on the Seedmatch platform in December last year. Within three hours the funding threshold of 100,000 euros had been exceeded and after only 21 days the target of 750,000 euros was reached: the fastest crowd investing in the life sciences sector in Germany. Now the amount has been doubled once again: the venture capital company bm|t, which already holds an interest in oncgnostics GmbH, is investing together with a group of private investors.

"oncgnostics' GynTect-Test addresses a billion-euro market. This investment enables the company to build up targeted sales and marketing activities and thus gain better access to this attractive market. In addition, oncgnostics has an attractive development pipeline, which will be further advanced with this capital. That is why we are happy to participate in this financing round," says Kevin Reeder, Managing Director of bm|t.

Better chances in early detection

GynTect quickly and reliably clarifies whether a patient actually develops or is suffering from cervical cancer. This facilitates risk assessment in cervical cancer screening: unnecessary, hasty operations can be avoided and the chances of early, successful therapy measures can be increased. Patients are relieved of their fears due to unclear findings from the current early detection of cervical cancer and rapid certainty is ensured.

"We are very pleased that we were able to convince existing and new investors of our concept of using epigenetic markers in cancer diagnostics and of the very good prospects for marketing our GynTect test. This gives us the opportunity to improve our market opportunities not only through increased international marketing but also through further product developments," said Dr. Alfred Hansel, Managing Director of oncgnostics GmbH.

Previous and future developments

The first successful steps in international marketing were taken with an exclusive license for GynTect in China and marketing and sales partnerships in Portugal, Slovakia and the Czech Republic. Further strategic partnerships, including in the USA, are being sought. In December 2017, a three-year study was launched together with ten research centers throughout Germany to prove the prognostic potential of the GynTect test. Another study on psychological stress in women with conspicuous Pap or HPV test results has just been completed. The results are expected to be published by the end of the year.

oncgnostics is also working with clinical partners on the development of tests for other cancers. The Thuringian company is working on the validation of markers for head and neck tumors and hopes to improve the early detection of ovarian cancer.

Facts, background information, dossiers
More about oncgnostics
  • News

    oncgnostics cooperates with the Medical University of Graz

    The biotechnology company oncgnostics GmbH is researching a method for diagnosing Head-and-Neck tumors together with the clinical department for general ENT at the Medical University of Graz as part of the “OroCa-Graz” study. 550,000 people worldwide develop carcinomas of this type every ye ... more

    oncgnostics starts international sales partnership with EUROIMMUN

    Biotechnology company oncgnostics GmbH is announcing a collaboration with the international diagnostics group EUROIMMUN, a PerkinElmer company. As part of the cooperation, EUROIMMUN will sell the cervical cancer test from oncgnostics GmbH, Gyn-Tect, in the European countries of Portugal, It ... more

    Oncgnostics GmbH obtains seed funding for financing preclinical and clinical trials

    Chemical alterations of the genetic information specifically occuring during carcinogenesis provide the basis for the innovative diagnostic tests that are developed by the newly established oncgnostics GmbH in Jena. These tests allow not only for an earlier, but also a more accurate detecti ... more

  • Companies

    oncgnostics GmbH

    The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers. oncgnostics GmbH is working according to ISO 13485 standards in research, development, p ... more